Overview of Preclinical and Clinical Trials of Nanoparticles for the Treatment of Brain Metastases
Authors:
- Muhammad IzharMIMuhammad Izhar
- Mohamed Al GharyaniMGMohamed Al Gharyani
- Ahed H. KattaaAKAhed H. Kattaa
- Juan J. CardonaJCJuan J. Cardona
- Ruchit P. JainRJRuchit P. Jain
- Elaheh ShaghaghianESElaheh Shaghaghian
- Yusuke S. HoriYHYusuke S. Hori
- Fred C. LamFLFred C. Lam
- Deyaaldeen Abu ReeshDRDeyaaldeen Abu Reesh
- Sara C. EmrichSESara C. Emrich
- Louisa UstrzynskiLULouisa Ustrzynski
- Armine TayagATArmine Tayag
Open Access
- 11 July 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (7) , 899
Abstract
Brain metastases (BM), which most commonly originate from lung, breast, or skin cancers, remain a major clinical challenge, with standard treatments such as stereotactic radiosurgery (SRS), surgical resection, and whole-brain radiation therapy (WBRT). The prognosis for patients with BM remains poor, with a median overall survival (OS) of just 10–16 months. Although recent advances in systemic therapies, including small molecule inhibitors, monoclonal antibodies, chemotherapeutics, and gene therapies, have demonstrated success in other malignancies, their effectiveness in central nervous system (CNS) cancers is significantly limited by poor blood–brain barrier (BBB) permeability and subtherapeutic drug concentrations in the brain. Nanoparticle-based drug delivery systems have emerged as a promising strategy to overcome these limitations by enhancing CNS drug penetration and selectively targeting metastatic brain tumor cells while minimizing off-target effects. This review summarizes recent preclinical and clinical developments in nanoparticle-based therapies for BM. It is evident from these studies that NPs can carry with them a range of therapeutics, including chemotherapy, immunotherapy, small molecule inhibitors, gene therapies, radiosensitizers, and modulators of tumor microenvironment to the BM. Moreover, preclinical studies have shown encouraging efficacy in murine models, highlighting the potential of these platforms to improve therapeutic outcomes. However, clinical translation remains limited, with few ongoing trials. To close this translational gap, future work must address clinical challenges such as trial design, regulatory hurdles, and variability in BBB permeability while developing personalized nanoparticle-based therapies tailored to individual tumor characteristics.Keywords
This publication has 156 references indexed in Scilit:
- Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK PathwayAdvanced Science, 2023
- Overcoming Mfsd2a‐Mediated Low Transcytosis to Boost Nanoparticle Delivery to Brain for Chemotherapy of Brain MetastasesAdvanced Healthcare Materials, 2021
- Autocatalytic Delivery of Brain Tumor–Targeting, Size‐Shrinkable Nanoparticles for Treatment of Breast Cancer Brain MetastasesAdvanced Functional Materials, 2020
- Targeted Delivery of Secretory Promelittin via Novel Poly(lactone‐co‐β‐amino ester) Nanoparticles for Treatment of Breast Cancer Brain MetastasesAdvanced Science, 2020
- Nanoparticles in the clinic: An updateBioengineering & Translational Medicine, 2019
- Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood–Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor‐Associated MacrophagesAdvanced Healthcare Materials, 2019
- Nanoparticles Surmounting Blood–Brain Tumor Barrier Through Both Transcellular and Paracellular Pathways to Target Brain MetastasesAdvanced Functional Materials, 2019
- Externally Induced Drug Release Systems with Magnetic Nanoparticle Carriers: An Emerging Field in NanomedicineAdvanced Therapeutics, 2018
- Two‐Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2‐Positive Breast CancerAdvanced Functional Materials, 2018
- Presentation, patterns of care, and survival in patients with brain metastasesCancer, 2010